CreativeOne Wealth LLC Makes New $1.04 Million Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

CreativeOne Wealth LLC bought a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 18,089 shares of the biopharmaceutical company’s stock, valued at approximately $1,035,000.

Other large investors also recently modified their holdings of the company. GAMMA Investing LLC grew its holdings in Halozyme Therapeutics by 96.6% during the second quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 254 shares during the period. International Assets Investment Management LLC bought a new position in shares of Halozyme Therapeutics during the 2nd quarter worth $33,000. Skandinaviska Enskilda Banken AB publ purchased a new stake in Halozyme Therapeutics in the 2nd quarter worth about $49,000. Toth Financial Advisory Corp bought a new stake in Halozyme Therapeutics in the 3rd quarter valued at about $57,000. Finally, FSC Wealth Advisors LLC purchased a new stake in Halozyme Therapeutics during the third quarter valued at about $65,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Insider Buying and Selling

In other news, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction on Wednesday, September 18th. The shares were sold at an average price of $62.03, for a total transaction of $620,300.00. Following the completion of the sale, the senior vice president now directly owns 173,756 shares of the company’s stock, valued at approximately $10,778,084.68. The trade was a 5.44 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Over the last three months, insiders have sold 60,000 shares of company stock worth $3,425,000. Insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Stock Performance

NASDAQ:HALO opened at $48.20 on Friday. The stock has a market cap of $6.13 billion, a P/E ratio of 15.96, a PEG ratio of 0.44 and a beta of 1.29. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32. The business’s 50-day moving average price is $53.28 and its two-hundred day moving average price is $53.67. Halozyme Therapeutics, Inc. has a twelve month low of $33.15 and a twelve month high of $65.53.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on HALO. Cowen reissued a “buy” rating on shares of Halozyme Therapeutics in a research report on Friday, October 18th. Piper Sandler increased their target price on Halozyme Therapeutics from $51.00 to $52.00 and gave the stock a “neutral” rating in a research report on Monday, November 4th. Benchmark reaffirmed a “buy” rating and issued a $60.00 price target on shares of Halozyme Therapeutics in a report on Thursday, August 8th. HC Wainwright reissued a “buy” rating and set a $68.00 price objective on shares of Halozyme Therapeutics in a report on Wednesday, November 20th. Finally, TD Cowen lifted their target price on Halozyme Therapeutics from $59.00 to $65.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. Four analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, Halozyme Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $61.11.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.